Abstract 317P
Background
Molecular characteristics are essential for the classification and grading of glioma. However, the majority of current understanding is based on public databases that might not accurately reflect the Asian population. Here, we studied the genetic landscape of Chinese glioma patients in hope to provide strong rationales for future molecular classification and prognosis of glioma.
Methods
Tissue samples from 81 glioma patients of which 21 (26%) were astrocytoma (A) and oligodendroglioma (O), 16 (20%) were anaplastic astrocytoma/oligodendroglioma (AO/AA), 32 (40%) were Glioblastoma (GBM), and 8 (10%) were diffuse midline glioma underwent next-generation sequencing with Acornmed panel including 808 cancer-relevant genes.
Results
We identified currently established molecular pathologic markers of glioma, including TP53 (41%),TERT (34%), IDH1/2 (30%), PTEN (19%), ATRX (18%), EGFR (16%), H3F3A (10%) and BRAF (6%). IDH mutations were frequent in A and O and were a major discriminate of biologic class (P=0.002). IDH-mutant A/O (grades II) were characterized by MGMT methylation, ATRX, and CIC mutations. AO/AA (grades III) were also IDH1/2-mutant, but instead are characterized by TP53, BRAF, and FUBP1 mutations. GBM typically lacked IDH1/2 mutations and demonstrated EGFR, PTEN, TP53, PIK3CA, and CDKN2A alterations, and TERT promoter mutations. Copy number variations as EGFR, PDGFRA, MET, KIT, which were also significantly associated with GBM but not used for clinical classification (P=0.001). Clinically actionable genetic alterations were detected in 80.95%, 81.25%, and 93.75% of A/O, AA/AO, and GBM, respectively.
Conclusions
We demonstrate that genes characterize the distinction between these pathologic subsets. These results further define molecular subsets of gliomas which may potentially be used for patient stratification and suggest potential targets for treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Li, H. Cheng, H. Wang, S. Cao: Full/Part-time employment: Beijing Acornmed Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session